Company intelligence / Profile preview

Tolmar International

Dublin, Ireland

Ownership: Private
Employees: ~600
Development stage: Other

Overview

Tolmar, recognized for its advanced long-acting injectable drug delivery capabilities, markets several injectable therapies—most notably leuprolide acetate (Eligard)—approved and commercialized for prostate cancer and central precocious puberty. They have both original and generic (NDA and ANDA) approvals, and recently expanded via asset acquisitions such as Jatenzo[2][4].

Therapeutic areas: OncologyEndocrinologyMen's Health
Modalities: Small moleculePeptideBiologicInjectable drug
Industry: Biotech

Partnerships

Notable collaborations likely, but partners not explicitly named in public sources[2][3]

Beyond the preview

Go deeper on Tolmar International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tolmar International.

Explore the full profile